L & S Advisors’s Immunocore IMCR Stock Holding History

L & S Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,796	Closed	-$1.35M	–	347
2024 Q1	$1.35M	Sell	20,796 -25	-0.1%	-$1.72K	0.15%	165
2023 Q4	$1.42M	Buy	+20,821	New	+$1.08M	0.17%	132

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

L & S Advisors's IMCR Position: Q2 2024 in Review

L & S Advisors sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 20,796 shares — an estimated $1.35M sold.

L & S Advisors first reported a position in IMCR in Q4 2023 and held it in 2 quarters. The position peaked at $1.42M in Q4 2023. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

L & S Advisors reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
L & S Advisors sold 20,796 Immunocore shares in Q2 2024, an estimated $1.35M.
L & S Advisors first reported a position in Immunocore in Q4 2023 and held it in 2 quarters.
L & S Advisors's Immunocore position peaked at $1.42M in Q4 2023.
138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on L & S Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.